Role of flow cytometry and especially its use in the definition of the measurable residual disease (MRD) in multiple myeloma

Basic Information

Funding Cycle : 2021-2022
Name : Laura Notarfranchi
Type of Award : Career Development Award
Home Institution : University of Parma, Italy
Host Institution : University of Navarra, Spain


This project aims to develop a clinically useful method for monitoring treatment response in multiple myeloma (MM) by detecting circulating tumor cells in peripheral blood (PB) using next-generation flow cytometry. The proposed approach, called BLOOD-FLOW, involves optimizing immunomagnetic enrichment of circulating plasma cells from large PB volumes, achieving a limit of detection two logs more sensitive than current methods. Specific objectives include developing an efficient enrichment protocol and validating its sensitivity and specificity in PB samples from 50 MM patients post-treatment, comparing its performance to bone marrow minimal residual disease assessment.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events